Thank you for your interest in post-marketing study information. The Post-Marketing Study Registration System on this website has ceased updates as of January 1, 2025, and related information is no longer provided on this platform.

For inquiries about post-marketing studies or related research information, we recommend exploring other resources that provide clinical trial information, such as the Taiwan Clinical Trials (TaiwanClinicalTrials.tw), clinical trial centers at major hospitals, or the website of Center for Drug Evaluation (https://www1.cde.org.tw/ct_taiwan/introduction.html).

We appreciate your understanding and continued support!

Company Name	Title of Study	Update Date
Pfizer	The Observational Registry: Nationwide Data Collection on Gastrointestinal Stromal Tumors (GISTs) Patients	2020-06-30
Daiichi Sankyo Taiwan Ltd.	Phase IV, non-comparative, open label, multicenter, 28-week switching study of prasugrel maintenance dose from clopidogrel in patients with acute coronary syndrome (ACS) who underwent a percutaneous coronary intervention (PCI) in Taiwan	2020-06-30
Bayer Taiwan Co., Ltd.	TAURUS: A MulTinational PhAse IV Study EvalUating “Real World” Treatment Pattern in Previously Treated Hemophilia A Patients Receiving KOVALTRY (Octocog alfa) for RoUtine ProphylaxiS.	2020-06-30
Bayer Taiwan Co., Ltd.	REFINE: Regorafenib observational study in hepatocellular carcinoma	2020-06-30
AbbVie Biopharmaceuticals GmbH Taiwan Branch	A Real-world, Prospective, Observational Study to Investigate the Clinical REsponses in Ankylosing Spondylitis Patients on Adalimumab Therapy in Taiwan (EAST)	2020-06-30
台灣田邊製藥	An open-label study to evaluate clinical efficacy and safety of canagliflozin in the treatment of type 2 diabetes uncontrolled with insulin therapy	2020-06-30
台灣田邊製藥	An open-label study to evaluate clinical efficacy and safety of canagliflozin in the treatment of type 2 diabetes uncontrolled with insulin therapy	2020-06-30
Boehringer Ingelheim Taiwan	Non-Interventional study (NIS) Collecting Experiences For IPF in Taiwan	2020-06-30
Boehringer Ingelheim Taiwan	Patients’ Assessment of Satisfaction for Stroke Prevention in Atrial FibrillationImpact of Conventional Oral Anticoagulant (OAC) Compared with Novel Oral Anticoagulant (NOAC)	2020-12-25
Takeda Taiwan	Safety and Effectiveness of Vedolizumab IV in Real World Clinical Practice in Taiwan: A Registry-Based Study	2020-12-25